These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 16499662

  • 1. IL-2 and IL-10 serum levels in HIV-1-infected patients with or without active antiretroviral therapy.
    Orsilles MA, Pieri E, Cooke P, Caula C.
    APMIS; 2006 Jan; 114(1):55-60. PubMed ID: 16499662
    [Abstract] [Full Text] [Related]

  • 2. Normalized CD8+ but not CD4+ lymphocyte IL-2 expression is associated with early treatment with highly active antiretroviral therapy.
    Akerele T, Galatowicz G, Bunce C, Calder V, Lynn WA, Lightman S.
    Clin Immunol; 2006 Nov; 121(2):191-7. PubMed ID: 16987710
    [Abstract] [Full Text] [Related]

  • 3. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
    Moore RD, Keruly JC.
    Clin Infect Dis; 2007 Feb 01; 44(3):441-6. PubMed ID: 17205456
    [Abstract] [Full Text] [Related]

  • 4. Altered clonogenic capability and stromal cell function characterize bone marrow of HIV-infected subjects with low CD4+ T cell counts despite viral suppression during HAART.
    Isgrò A, Leti W, De Santis W, Marziali M, Esposito A, Fimiani C, Luzi G, Pinti M, Cossarizza A, Aiuti F, Mezzaroma I.
    Clin Infect Dis; 2008 Jun 15; 46(12):1902-10. PubMed ID: 18462177
    [Abstract] [Full Text] [Related]

  • 5. T-cell homeostasis alteration in HIV-1 infected subjects with low CD4 T-cell count despite undetectable virus load during HAART.
    Marziali M, De Santis W, Carello R, Leti W, Esposito A, Isgrò A, Fimiani C, Sirianni MC, Mezzaroma I, Aiuti F.
    AIDS; 2006 Oct 24; 20(16):2033-41. PubMed ID: 17053349
    [Abstract] [Full Text] [Related]

  • 6. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
    Srasuebkul P, Ungsedhapand C, Ruxrungtham K, Boyd MA, Phanuphak P, Cooper DA, Law MG.
    HIV Med; 2007 Jan 24; 8(1):46-54. PubMed ID: 17305932
    [Abstract] [Full Text] [Related]

  • 7. Relationship of in vivo and ex vivo levels of TH1 and TH2 cytokines with viremia in HAART patients with and without opportunistic infections.
    Sindhu S, Toma E, Cordeiro P, Ahmad R, Morisset R, Menezes J.
    J Med Virol; 2006 Apr 24; 78(4):431-9. PubMed ID: 16482539
    [Abstract] [Full Text] [Related]

  • 8. The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328.
    Mitsuyasu R, Gelman R, Cherng DW, Landay A, Fahey J, Reichman R, Erice A, Bucy RP, Kilby JM, Lederman MM, Hamilton CD, Lertora J, White BL, Tebas P, Duliege AM, Pollard RB, AIDS Clinical Trials Group 328 Study Team.
    Arch Intern Med; 2007 Mar 26; 167(6):597-605. PubMed ID: 17389292
    [Abstract] [Full Text] [Related]

  • 9. Comparative analysis of T-cell turnover and homeostatic parameters in HIV-infected patients with discordant immune-virological responses to HAART.
    Marchetti G, Gori A, Casabianca A, Magnani M, Franzetti F, Clerici M, Perno CF, Monforte Ad, Galli M, Meroni L.
    AIDS; 2006 Aug 22; 20(13):1727-36. PubMed ID: 16931937
    [Abstract] [Full Text] [Related]

  • 10. Residual viraemia in HIV-1-infected patients with plasma viral load <or=20 copies/ml is associated with increased blood levels of soluble immune activation markers.
    Ostrowski SR, Katzenstein TL, Pedersen BK, Gerstoft J, Ullum H.
    Scand J Immunol; 2008 Dec 22; 68(6):652-60. PubMed ID: 19055701
    [Abstract] [Full Text] [Related]

  • 11. HIV-1-infected children on HAART: immunologic features of three different levels of viral suppression.
    Zaccarelli-Filho CA, Ono E, Machado DM, Brunialti M, Succi RC, Salomão R, Kallás EG, de Moraes-Pinto MI.
    Cytometry B Clin Cytom; 2007 Jan 15; 72(1):14-21. PubMed ID: 17041945
    [Abstract] [Full Text] [Related]

  • 12. Impact of baseline viral load and adherence on survival of HIV-infected adults with baseline CD4 cell counts > or = 200 cells/microl.
    Wood E, Hogg RS, Yip B, Moore D, Harrigan PR, Montaner JS.
    AIDS; 2006 May 12; 20(8):1117-23. PubMed ID: 16691062
    [Abstract] [Full Text] [Related]

  • 13. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R, Pogány K, Fernandez Garcia E, Jurriaans S, Brinkman K, Schuitemaker H, Miedema F, Lange JM, Prins JM.
    AIDS; 2008 Aug 20; 22(13):1583-8. PubMed ID: 18670217
    [Abstract] [Full Text] [Related]

  • 14. Long-term clinical and surrogate marker effects of subcutaneous intermittent interleukin-2 without antiretroviral therapy in HIV-infected patients.
    Herzmann C, Cuthbertson Z, Fosdick L, Fisher M, Nelson M, Perry N, Law M, Wand H, Janossy G, Johnson MA, Youle M.
    J Antimicrob Chemother; 2008 Sep 20; 62(3):583-6. PubMed ID: 18587135
    [Abstract] [Full Text] [Related]

  • 15. Down-regulation of interleukin-7 receptor (CD127) in HIV infection is associated with T cell activation and is a main factor influencing restoration of CD4(+) cells after antiretroviral therapy.
    Benito JM, López M, Lozano S, González-Lahoz J, Soriano V.
    J Infect Dis; 2008 Nov 15; 198(10):1466-73. PubMed ID: 18847371
    [Abstract] [Full Text] [Related]

  • 16. Absence of favourable changes in circulating levels of interleukin-16 or beta-chemokine concentration following structured intermittent interruption treatment of chronic human immunodeficiency virus infection.
    Montes de Oca Arjona M, Pérez Cano R, Orozco MJ, Martín Aspas A, Guerrero F, Fernández Gutiérrez Del Alamo C, Girón-González JA.
    Clin Microbiol Infect; 2005 Jan 15; 11(1):57-62. PubMed ID: 15649305
    [Abstract] [Full Text] [Related]

  • 17. Immunophenotype of HIV+ patients during CD4 cell-monitored treatment interruption: role of the IL-7/IL-7 receptor system.
    Nemes E, Lugli E, Nasi M, Ferraresi R, Pinti M, Bugarini R, Borghi V, Prati F, Esposito R, Cossarizza A, Mussini C.
    AIDS; 2006 Oct 24; 20(16):2021-32. PubMed ID: 17053348
    [Abstract] [Full Text] [Related]

  • 18. Effect of highly active anti-retroviral therapy and hepatitis C virus co-infection on serum levels of pro-inflammatory and immunoregulatory cytokines in human immunodeficiency virus-1-infected individuals.
    Tornero C, Alberola J, Tamarit A, Navarro D.
    Clin Microbiol Infect; 2006 Jun 24; 12(6):555-60. PubMed ID: 16700705
    [Abstract] [Full Text] [Related]

  • 19. Interleukin-7 (IL-7): immune function, involvement in the pathogenesis of HIV infection and therapeutic potential.
    Beq S, Delfraissy JF, Theze J.
    Eur Cytokine Netw; 2004 Jun 24; 15(4):279-89. PubMed ID: 15627636
    [Abstract] [Full Text] [Related]

  • 20. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
    Li H, Zheng YH, Shen Z, Liu M, Liu C, He Y, Chen J, Ou QY, Huang ZL.
    Zhonghua Yi Xue Za Zhi; 2007 Nov 13; 87(42):2973-6. PubMed ID: 18261327
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.